Article
Chemoprevention of breast cancer.
The Surgical clinics of North America - 1 Oct 1999
Osborne M P
Abstract excerpt
A critical question is, why do the European studies fail to confirm the US study? Clearly, the answers are complex and uncertain. Differences in power, age, risk, compliance, the use of ERT, and follow-up in the European studies may all be relevant. The efficacy of tamoxifen in BRCA 1 or 2 carriers is an important issue; recent data have shown a DNA repair defect in those with BRCA 1 gene alterations. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
